| Activity |
|---|
| Catalytic type | Serine |
| Peplist | Included in the Peplist with identifier PL00319 |
| NC-IUBMB | Subclass 3.4 (Peptidases) >> Sub-subclass 3.4.21 (Serine endopeptidases) >> Peptidase 3.4.21.73
|
| Enzymology | BRENDA database |
| Proteolytic events | CutDB database (7 cleavages) |
| Activity status | human: active (Ellis, 2004)
mouse: active (Skriver et al., 1982)
|
| Inhibitors | Not trapped by alpha-2-macroglobulin (Barrett 1981). |
| Physiology | Activates plasminogen to plasmin in fibrinolysis. |
| Knockout | Knockout mice appear to be normal when maintained under ideal, non-stressful conditions, but show a variety of abnormalities, including a peculiar predisposition to a rare bacterial infection (Shapiro et al., 1997). Mice with combined t-plasminogen activator (S01.232) and u-plasminogen activator deficiency suffer extensive spontaneous fibrin deposition, with effects on growth, fertility and survival (Carmeliet et al., 1994). |
| Pharmaceutical relevance | It has been reported that down-regulation of expression of both cathepsin B and u-plasminogen activator has anti-tumour activity in experimental systems (Gondi et al., 2004). |
| Pathways |
KEGG | Complement and coagulation cascades |
|
KEGG | MicroRNAs in cancer |
|
KEGG | Proteoglycans in cancer |
|
KEGG | Transcriptional misregulation in cancer |
|
Other databases
| WIKIPEDIA | http://en.wikipedia.org/wiki/Urokinase |
| Cleavage site specificity |
Explanations of how to interpret the
following cleavage site sequence logo and specificity matrix can be found here. |
|---|
| Cleavage pattern | -/s/gs/Rk g/lrv/-/ng (based on 19 cleavages) |
